Guerbet

This study looked at the safety of using Lipiodol® Ultra Fluid (a contrast dye) together with surgical glues to block abnormal blood vessels in 132 adults with conditions like hemangiomas or arteriovenous malformations. The procedure was done as part of their regular treatment pl…

This completed Phase 3 trial tested gadopiclenol, a new MRI contrast agent, in 240 Japanese adults and children with known or suspected lesions in the brain or body. The study compared a lower dose of gadopiclenol to a standard dose of gadobutrol to see if it could provide equall…

This completed Phase 3 trial tested whether Elucirem (gadopiclenol) provides better MRI images of brain gliomas compared to the standard contrast agent Dotarem. 138 adults with primary or recurrent brain tumors received one of the two agents during DSC-MRI perfusion scans. The ma…

This study tested a contrast agent called gadopiclenol in 36 infants under 2 years old who needed an MRI. The goal was to see how the drug behaves in their bodies and check for safety. The children received a single injection before their MRI, and researchers measured drug levels…

This Phase 3 trial tested a new contrast agent called gadopiclenol for body MRI scans. 324 adults with known or suspected lesions received gadopiclenol and were compared to unenhanced MRI and a standard contrast agent. The goal was to see if gadopiclenol improves how well doctors…

This Phase 3 trial tested a new contrast agent called gadopiclenol for MRI scans of the brain and spine. The study involved 260 people with known or suspected central nervous system lesions. The goal was to see if gadopiclenol improves the visibility of lesions compared to scans …